CEACAM5 and ovarian carcinoma: Direct administration of MV-CEA (five doses of 107 pfu/dose in two weeks) in subcutaneous human ovarian carcinoma xenografts (SKOV3ip.1 cells) with a diameter of approximately 0.5 cm in athymic mice induced complete regression in 80% of the tumors [137].